Boston Trust Walden Corp Sells 6,447 Shares of Core Laboratories Inc. (NYSE:CLB)

Boston Trust Walden Corp trimmed its stake in shares of Core Laboratories Inc. (NYSE:CLB) by 1.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 610,889 shares of the oil and gas company’s stock after selling 6,447 shares during the quarter. Boston Trust Walden Corp owned approximately 1.31% of Core Laboratories worth $9,157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in CLB. Principal Financial Group Inc. grew its stake in Core Laboratories by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 229,096 shares of the oil and gas company’s stock worth $3,966,000 after purchasing an additional 6,827 shares during the period. Kornitzer Capital Management Inc. KS acquired a new stake in Core Laboratories during the fourth quarter worth approximately $615,000. Exchange Capital Management Inc. grew its stake in Core Laboratories by 4.6% during the fourth quarter. Exchange Capital Management Inc. now owns 68,138 shares of the oil and gas company’s stock worth $1,179,000 after purchasing an additional 3,024 shares during the period. Smartleaf Asset Management LLC grew its stake in Core Laboratories by 173.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company’s stock worth $35,000 after purchasing an additional 1,293 shares during the period. Finally, Jones Financial Companies Lllp grew its stake in Core Laboratories by 10.6% during the fourth quarter. Jones Financial Companies Lllp now owns 16,383 shares of the oil and gas company’s stock worth $284,000 after purchasing an additional 1,569 shares during the period. Institutional investors and hedge funds own 97.81% of the company’s stock.

Core Laboratories Trading Down 0.3%

Shares of Core Laboratories stock opened at $12.62 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.64 and a current ratio of 2.21. Core Laboratories Inc. has a 52 week low of $10.14 and a 52 week high of $25.13. The stock has a 50 day moving average price of $11.75 and a two-hundred day moving average price of $15.03. The stock has a market capitalization of $591.53 million, a PE ratio of 21.39, a price-to-earnings-growth ratio of 3.87 and a beta of 1.40.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, April 23rd. The oil and gas company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Core Laboratories had a net margin of 5.41% and a return on equity of 15.06%. The firm had revenue of $123.59 million during the quarter, compared to analyst estimates of $125.09 million. During the same period last year, the business posted $0.19 EPS. The company’s revenue was down 4.7% on a year-over-year basis. As a group, equities analysts anticipate that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, May 27th. Stockholders of record on Monday, May 5th were issued a $0.01 dividend. The ex-dividend date was Monday, May 5th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.32%. Core Laboratories’s dividend payout ratio is presently 6.78%.

Wall Street Analyst Weigh In

Several research firms recently commented on CLB. Citigroup decreased their target price on Core Laboratories from $16.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. Stifel Nicolaus decreased their target price on Core Laboratories from $19.00 to $15.00 and set a “hold” rating for the company in a research note on Tuesday, April 15th. Finally, Wall Street Zen cut Core Laboratories from a “hold” rating to a “sell” rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.00.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.